
Pharmacally
Rheumatoid Arthritis
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Rheumatoid Arthritis
Clinical TrialsLynk Reports Positive 76-Week Zemprocitinib Results in Rheumatoid ArthritisLynk Pharmaceuticals reports sustained zemprocitinib responses through week 76 in Phase III COURAGE-RA, with efficacy and long-term safety limitations. Written…Fact-Checked
Health TidingsForward Reports Positive Phase 1 Data for FT2109, Advances to Phase 2 in Rheumatoid ArthritisForward Therapeutics reported favorable Phase 1 safety, tolerability and pharmacokinetic findings for oral TNFR1 signaling inhibitor FT2109 in healthy participants, supporting advancement into Phase 2 development.Fact-Checked
Clinical TrialsResomelagon Shows Clearer Efficacy Signal in Post-Hoc Rheumatoid Arthritis AnalysisSynAct Pharma’s post-hoc Phase 2b ADVANCE analysis found that resomelagon 40 mg plus methotrexate produced a stronger ACR20 response than placebo plus methotrexate in treatment-naïve patients with highly…Fact-Checked
Clinical TrialsSpyre’s SPY072 Shows Efficacy Signals in Rheumatoid Arthritis, but Falls Short of Monotherapy BarSpyre Therapeutics’ SPY072 demonstrated proof-of-mechanism and statistically significant benefits on selected endpoints in the Phase 2 SKYWAY-RA trial, but the treatment effect did not meet the company’s threshold…Fact-Checked
Mergers & AcquisitionsChemomab, Scipher Merge to Advance Nebokitug in Rheumatoid ArthritisChemomab Therapeutics and Scipher Medicine will merge to create Scipher Medicine Corporation, focused on precision medicine in autoimmune disease.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.